Introduction
Juvenile myoclonic epilepsy (JME) is a common epilepsy syndrome that is classified among the idiopathic generalized epilepsies (IGEs). It is a collection of seizure patterns that are clinically distinct from those in other forms of IGE, with the major characteristic being adolescence-onset myoclonic seizures. Although the pathogenesis is unknown, recent advances, especially in genetics, suggest several possible mechanisms. JME is both genetically and clinically heterogeneous; some clinical differences may indicate differences in pathogenesis in different groups of patients. The nosology and classification of IGE syndromes are currently under revision. 1, 2 The original description by Janz and co-workers 3 distils the essential clinical features of this syndrome: ''(epilepsy with) impulsive petit mal appears around puberty and is characterized by seizures with bilateral, single or repetitive arrhythmic, irregular myoclonic jerks, predominantly in the arms. Jerks may cause some patients to fall suddenly. No disturbance of consciousness is noticeable. Often there are generalized tonic-clonic seizures (GTCS) and infrequent absences. The seizures usually occur after awakening and are often precipitated by sleep deprivation. Interictal and ictal EEG have rapid generalized, often irregular spike waves and polyspike waves; there is no close phase correlation between EEG spikes and jerks. Frequently the patients are photosensitive. Response to appropriate drugs is good''.
In the last few years, over half a dozen studies have reported on the phenotypic expression of the JME syndrome in people hailing from the North, North-Western and Southern parts of India. [4] [5] [6] [7] [8] [9] [10] [11] To date, no report has emerged from the Eastern part of India and certainly not looking at the phenotypic expression of the disease in a specific ethnic group. The present study looks at the clinical aspects of JME in ethnic Bengalees from the Eastern Indian state of West Bengal in a clinic based study specifically focussing on the natural history of the disease only enrolling patients where follow up data had been available for 5 years or more.
Material and methods
The present clinic based study has been carried out through retrospective analysis of case notes of 200 patients of ethnic Bengalee origin with JME, attending the general neurology outpatient department of the Institute who had completed 5 years or more of follow up by December, 2004. The cases were first seen at various times between 1995 and 2000 and included 162 newly diagnosed cases and 38 diagnosed as epilepsy earlier elsewhere. Cases who were not regularly followed up or had inadequate data or were inadequately investigated were excluded. Where needed, patients were contacted to get details of clinical history and family histories at the time of compilation of the results (JanuaryMarch 2005). As the present study cannot provide any indication of the incidence of JME amongst our epilepsy patients, the total number of 'new' JME cases in ethnic Bengalees first seen in 4 years between 2000 and 2003 (N = 385) vis a vis the total number of 'new' cases of epilepsy in ethnic Bengalees seen (N = 3564) during the same period were noted for analysis.
Although, the present study is essentially a retrospective one, a uniform pattern of assessment of JME patients was evolved much earlier in keeping with our interest in this particular syndrome.
The inclusion criteria for JME being 12 : (a) unequivocal clinical (historical) evidence of bilateral myoclonic jerks (MJ) beginning in or around early teens with or without GTCS and/or absence seizures; (b) no evidence of neurologic or intellectual deficit; (c) abnormal EEG consisting of generalized spike and/or multiple spike-wave discharges in untreated or treated patients (a normal EEG or with background abnormalities other than well-defined spike-wave discharges was acceptable only if the above-mentioned clinical criteria were strictly justified); and (d) normal computed tomography (CT)/magnetic resonance imaging (MRI) scan (occasional minor abnormalities that could not have been the cause of the seizures after the relevant investigations were acceptable). Patients with evidence of neurologic or intellectual deficit or an abnormal CT/MRI of the brain that could explain the seizure types, and those with evidence of MJ and/or GTCS secondary to alcohol withdrawal, substance abuse, brain hypoxia, metabolic disease, meningo-encephalitis, degenerative disease, etc. were excluded.
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After initial evaluation, all patients who satisfied all the criteria for diagnosis of JME, the case notes were studied, recording the type and frequency of seizures, precipitating factors for seizures, EEG might account for genetic heterogeneity noted in molecular genetic studies. JME cannot really be called a very 'benign' epileptic syndrome; recurrence after therapy withdrawal almost invariably occurs. # 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved. data, antiepileptic drug (AED) treatment details and family history. Some patients were recalled for further evaluation where initial assessment details seemed inadequate.
At least one conventional scalp EEG following sleep deprivation with hyperventilation and intermittent photic stimulation (IPS) was recorded (without modification of their current antiepileptic treatment, if any) on all the probands on presentation. The IPS was performed using a photic stimulator with stimulator lamp at a distance of 30 cm from the nasion. The IPS frequencies tested were 5, 10, 15, 20, 25, and 30 Hz in an ascending order with eyes closed for all the frequencies. The same person with the knowledge of the patient's diagnosis reported all the EEGs that were classified as 'abnormal' only when definite bilaterally symmetrical, generalized spike-wave or polyspike and slow-wave discharges (including photo-convulsive response (PCR)) were seen. PCR on the EEG was defined as occurrence of generalized spike, spike-wave or polyspike and wave discharges frequently locked with the stimulus, consistently elicited by IPS and on occasions outlasting the IPS. CT/MRI of the brain was performed in all patients and all were normal or revealed unrelated findings.
Details of family history were elicited specially is relation to first and second degree relatives and pedigree charts were drawn. When possible, affected family members were personally examined to elicit the type of epileptic seizure and make a syndromic diagnosis in some (not all) through usual investigations (EEG, CT).
The treatment schedule followed had been formulated earlier. All patients without any AED treatment (n = 162) were started on Sodium Valproate 15 mg/kg BW and the dosage was gradually increased till adequate seizure control was achieved or any significant side effects developed. Patients already on Sodium Valproate (n = 8) were allowed to continue on same treatment with dosage adjustment made as and when required. Patients on other AED (phenytoin, carbamazepine) with inadequate control of seizures (n = 6) were changed to Sodium Valproate gradually. However those with adequate seizure control but on other AED (n = 24) were allowed to continue the same treatment and result assessed clinically and electroencephalographically at 1 year. All female patients received routine Folic Acid supplements.
Three monthly follow ups were made in all cases and the results assessed clinically and electroencephalographically at 1 year, 2 years and 3 years. At 1 year, in those with inadequate control on Valproate monotherapy, either dosage was increased to upto 40 mg/kg BW or a second line AED, e.g. Clobazam or Lamotrigine added. In patients with adequate control on other AED, those with abnormal EEG at 1 year were changed over to Valproate monotherapy gradually.
At 3 years follow up, those with seizure freedom for 3 years and normal interictal EEG record (with provocative measure outlined above) on two successive occasions at 6 weeks intervals were given the choice of AED withdrawal. In those who consented, AED withdrawal was attempted slowly, at a rate approximately 5 mg/kg BW every 6 weeks and the outcomes noted. Those who relapsed were put back on their original drug regime.
During the course of Valproate therapy, in female subjects, menstrual abnormalities were noted in approximately 30% of subjects. Inadequacy of fundings, prevented detailed endocrinological and ultrasound examination of all these subjects. Only those developing phenotypic Polycystic Ovarian Disease (PCOD) at 2 years follow up were fully investigated with help from gynaecological colleagues. In such cases (n = 16), attempt was made to change the therapy from Valproate monotherapy to Clobazam monotherapy and the outcome recorded.
During the course of therapy and follow up, amongst female patients with JME on Valproate monotherapy, 12 patients became pregnant. The pregnancy outcome of these patients will be mentioned.
Results
Between 2000 and 2003, 3564 'new' patients with epilepsy with age of onset above 5 years were encountered. JME constituted 385 cases (M:F = 1:1.79) giving an incidence of 11% in our hospital based sample of ethnic Bengalees.
The present report however deals with only 200 patients recruited between 1995 and 2000 where detailed follow up data were available for 5 years or more (range 5-9 years; mean 6.8 years). There were 68 males and 132 females with a M:F ratio of 1:1.94.
Clinical phenomenology
This is summarized in Tables 1-3 . Age at onset for MJ and GTCS had been similar but absence seizures when present, occurred a little earlier. MJ occurred Awakening and sleep deprivation appeared to be the commonest precipitating factors for either MJ or GTCS. Some relationship to menstrual cycle could be established in few patients (7.5%) and examination related stress in 2.5% cases only. Although TV watching precipitated attacks in a minority (3.5%) of patients, none had attacks while working on computers.
EEG characteristics
Generalized symmetrical bursts of polyspikes and spike waves dominated the interictal records of most patients at initial evaluation. Fifteen percent showed generalized bursts of high amplitude (>100 mV) delta waves. Only a minority (2%) showed definite photo-convulsive response. None showed any focal features (Table 4) . EEG features during follow up at 1 year and 2 years are given in Table 5 .
AED regime
The principles of drug therapy in the cases studied have already been mentioned previously. The drug regime followed by the 200 patients at 1-year follow up is detailed in Table 6 . Most had been receiving Valproate monotherapy. Twelve percent of patients were still seizure free on other AED like phenytoin and carbamazepine. As depicted in Table 5 , although remaining seizure free, in none the interictal EEG reverted to normal at 1 year. All these patients were subsequently changed over to Valproate monotherapy with improvement in EEG outcome.
The therapy results as evaluated at 3 years follow up are shown in Table 7 . Seventy-five percent patients remained totally seizure free on Valproate monotherapy alone in most and Clobazam monotherapy in a few (see below). However 6% of patients appeared to be poor responders with not too infrequent myoclonic jerks on awakening and even GTCS. Most of these patients had multiple seizure types at initial evaluation and were maintained on a high dose (upto 40 mg/kg BW) of Valproate with or without either Clobazam or Lamotrigine as add on. a None of these cases had a normal EEG at 1 year; all cases were gradually changed over to Valproate monotherapy with normalization of EEG at 2 years follow up ( Table 5 ).
The causes of less than desirable seizure control in 48 out of 200 patients (i.e. 24%) were looked into by careful reviewing of their medical records. In the group of 16 patients (8%) with >90% seizure freedom, only very occasional MJ occurred almost always precipitated by sleep deprivation. The group (n = 20, i.e. 10%) with 'Fair Response' (50-90% control) was attributed to some reduction in dosage needed for gastric intolerance (n = 3) and rising levels of liver enzymes (n = 5) and occasional noncompliance in some (n = 2). However in 10 patients, no clear explanation was apparent. Similarly in the 'Poor Responder' group of 12 patients (6%), 4 patients declined to have any add ons to Valproate (due to cost factor), but in the remaining 8 patients control had been much less than optimal even with add ons and no cause was apparent. Thus, in out of 48 patients with less than total seizure control at 3 years follow up, the exact reason for suboptimal therapy response was not apparent in 18 (18/48, i.e. 37.5%) of subjects. This undoubtedly points towards the phenomenon of clinical heterogeneity (pharmacogenetic) amongst JME patients even hailing from the same ethnic background. This will be commented upon later in the article as well.
Results of therapy withdrawal after 3 years seizure freedom
Out of over 150 patients who were totally seizure free for 3 years or more with at least two normal interictal EEG (done 6 weeks apart with provocative techniques outlined earlier), only 130 patients (or their parents) consented to gradual reduction in drug dosage with a view to total withdrawal over a 6 months period. The results as assessed at 5 years follow up are shown in Table 8 .
As is noted, unfortunately, in 100% patients, seizures recurred; nearly 75% recurrences occurred during tapering (when dosage fell below 10 mg/kg BW) or within 1 year of total withdrawal. The rest recurred, after 1 year of drug withdrawal. MJ recurred in 66% cases and GTCS recurred in 34% cases at first. Most had both of them subsequently. All such patients were put back to their original drug regime with total or near total seizure control at 5 years follow up.
Pregnancy outcome
During the study period 12 patients experienced their first pregnancy. All had total seizure freedom for at least 2 years, with normal EEG and were on Valproate monotherapy (dosage 1000-1200 mg daily) and received Folic Acid supplementation. None experienced any seizure recurrence during pregnancy or in the post-partum period. All underwent USG pelvis and serum a-fetoprotein estimation at 16 weeks to assess any fetal abnormality. All were delivered by LUCS. Eleven out of 12 patients delivered full term normal fetuses. Only one patient delivered a cyanotic child who on echocardiography and catheter study was diagnosed to have tricuspid atresia. While waiting for surgery, the baby died on the 21st day after birth.
JME, Valproate and PCOD
Although menstrual irregularities were observed in about 30% of subjects on Valproate monotherapy, these were not investigated in detail. Only 16 patients developed phenotypic features (Table 9) suggestive of PCOD at 2 years follow up. Attempt was made to switch over these patients to Clobazam
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A. Chakravarty et al. monotherapy and the results are shown in Table 10 . Seizures recurred in seven, who were put back on Valproate. Nine patients were successfully switched over and remained seizure free (Table 10 ). All nine patients had regular menstruation established within 3 months of switch over and after 1 year showed regression of PCO features by pelvic ultrasound. Reduction of hirsutism and obesity were noted in six of nine patients. The reasons for choosing Clobazam had been the easy availability of the drug in India, lower cost and absence of any major side effects and lesser need for close hematological and other biochemical monitoring (as had been our past experience) thereby further reduction in cost of therapy. Also menstrual irregularities had never been found by us in the past, in women on Clobazam monotherapy with other forms of IGE where Valproate could not be prescribed (mostly due to gastric intolerance) or needed to be withdrawn (e.g. occurrence of viral hepatitis, raised liver enzymes, raised serum ammonia, etc.).
Family study
Amongst these 200 patients, only in 32 (16%) cases a positive family history of idiopathic epileptic seizures in first (20 cases) and second (12 cases) degree relatives could be elicited. Out of these only 20 first degree relatives could be personally examined and investigated. Of these, only 6 conformed to the diagnosis of JME and the rest 14 were ascribed to have IGE. In no families a clear Mendelian pattern could be established and none of the patients' parents were affected. The onset symptom of all six cases with JME had always been with morning MJ on awakening or precipitated by sleep deprivation. None had absence seizure. GTCS occurred at some stage in all patients. The onset age of MJ and GTCS matched those noted for the patient population. The other 14 patients had only GTCS and never any MJ or absences. The onset age varied from 18 to 22 years (mean 19.5 AE 1.6), a figure higher than that reported for GTCS in the patients under study. The EEG in the six patients with JME showed the typical features but none showed photo-convulsive responses. In the IGE group (n = 14), nine had normal interictal record and in five symmetrical bursts of spikes or sharp waves were recorded; and none had polyspikes or spike-wave changes.
Discussion
The present study, though clinic based and carried out amongst a relatively modest number of patients is the only Indian study carried out amongst people of a particular ethnic group. The importance of carrying out phenomenological studies in a particular ethnic group will be highlighted later in relation to known genetic abnormalities detected so far in JME. Secondly, this also is the only Indian study to give follow up data specially highlighting the issue of drug withdrawal. Furthermore, the study throws some light on the controversial issues of relationship of PCOD to AED therapy and AED teratogenicity.
The overall incidence of JME, at least in hospital based population, in the present study in ethnic Bengalees is not much different from figures quoted from elsewhere in the world. [13] [14] [15] [16] [17] [18] However, the incidence, appears to be higher than those reported from South India, North-Western India 9 and in one North Indian study. 10 However, it approaches the figure quoted by Jain et al. 11 from All India Institute of Medical Sciences (AIIMS) in New Delhi in North India.
Also, to note is the little higher prevalence of females with JME, amongst ethnic Bengalees than in other parts of India. [4] [5] [6] [7] [8] [9] [10] [11] Diagnostic delay in JME is well known. From India, Panagariya et al. 9 and Mehndiratta and Agarwal 10 gave specific figures in years for this delay in their study patients. Although we were aware of such diagnostic delays in many (if not most) of our patients we were unable to arrive at such specific figures and wonder how the latter workers could arrive at such specific figures. In absence of a nationalized health care system in India patients very often move from one doctor to another and from one hospital to another often for no apparent reason. The records handed over to most patients generally bear no mention of any diagnostic label or simply a diagnosis of epilepsy without any mention of the seizure or syndromic diagnosis. It is obvious that in the patients in the study who were on AEDs other than Valproate at the time of initial evaluation, the diagnosis of JME was not made. However, other patients were put on Valproate elsewhere before they attended our clinic and it was impossible to be sure whether such therapy was prescribed after making a specific diagnosis of JME or not.
The clinical phenomenology of seizure types, EEG abnormalities and precipitating factors are much the same as those reported by other centers from India 4-11 and elsewhere. [13] [14] [15] [16] [17] [18] The present study also confirms the unequivocally beneficial effect of Valproate in the management of JME patients. However, a number of patients, treated elsewhere were on other AED and enjoyed total seizure freedom. In none of them, the EEG normalized after 1 year and switching the AED regime to Valproate did reverse the EEG changes to normal at 2 years follow up. It is therefore suggested that all patients with JME need to be treated with Valproate, even though they may have clinical improvement on other AEDs. The most frustrating thing, which came out of the study had been the results of drug withdrawal. All patients in whom such attempts were made, had recurrence of seizures sooner or later. This is a major factor of concern in management and patients need to be counseled properly regarding the likely probability of indefinite treatment. 19 If recurrence occurs, these patients need to be treated with adequate dosage of Valproate (at least 15-20 mg/kg BW) and we do not subscribe to the view expressed by Panagariya et al. 9 to leave the patients on a smaller dosage of the drug.
The earlier study by De Toffel and Autret, 20 where treatment with low dose sodium Valproate was suggested included only 11 patients, followed up for only 33 months and continuation of myoclonic jerks was not taken into account. We firmly believe, that if one needs to treat a patient, treatment should be adequate and as full proof as possible.
A further point or concern relates to the small subset of patients who seemed to have a relative resistance to Valproate. Drug resistance in JME has been reported earlier by Gelisse et al. 21 and this occurred in 15.5% of their patients (N = 155). They identified clinical features associated with drug resistance namely presence of psychiatric problems and multiple seizure types (except MJ with absences). In the present study 16% patients had not had very satisfactory seizure control and of these 6% had been really poor responders. Out of these 32 patients none had MJ alone or MJ with absence. The figure includes 4/5 of the patients with MJ + absence + GTCS and the rest had MJ + GTCS (28/184) . In all these patients, though GTCS were near totally controlled, MJ continued to occur at 5 years follow up at times. A variable response to therapy within a group of phenotypically similar patients having a similar ethnic background needs worth noting and might point to genetic heterogeneity even within a same ethnic population.
It still remains controversial whether AEDs (specially Valproate) cause PCOD in young women. 22 Without getting involved into the controversy whether the drug or the disease is related to development of PCOD, in the present study 16/132 female patients had frank features of PCOD. Whether this matches the incidence of PCOD in general population or not is a difficult question but it is interesting to note two observations. Firstly all 16 patients had Valproate monotherapy and none in the group treated with other AEDs developed PCOD. Secondly, in about half of these patients, the PCOD features regressed when Valproate was replaced by Clobazam. These observations may lend indirect support to the view of association of Valproate therapy with development of PCOD. Isojervi et al. 23 previously suggested such change over with good results.
Valproate teratogenicity is well known. One patient out of 12 delivered an abnormal fetus with a congenital heart disease. It is surprising that this anomaly was missed prenataly by USG and developed even when the mother was on Folic Acid. The problem of JME, Valproate therapy and teratogenicity would continue to be a tricky one as most patients are young females in the reproductive phase of their lives.
Out of 200 patients studied, only 32 had a family history of epilepsy in a first or second degree relative. This figure is almost half of what had been quoted by Jain et al. 11 Out of these, only 20 could be, personally examined. Only six conformed to the diagnostic criteria of JME and the rest were ascribed as cases of IGE. No patients had any clear Mendelian pattern of inheritance and none had any affected parent with epilepsy. Also the relatives with IGE had a different EEG pattern. These findings underscore the importance of genetic heterogeneity of JME and the need for carrying out genetic studies in monoethnic population. One contributory factor accounting partly for this difference with Jain et al.'s 11 study might had been that those workers included febrile convulsions and single seizures as well in their overall figures. Also, secondary seizures were included but none such were encountered in the present study.
Several features noted in the present study, including variability of seizure types, rather low incidence of familial occurrence and identification of a subpopulation of patients with relative Valproate resistance, might point towards phenotypic variation in disease expression even within a specific ethnic population. This would be in keeping with the genetic heterogeneity of JME as reported in recent literature. [24] [25] [26] [27] [28] [29] [30] Furthermore, we feel that JME cannot really be called a very ''benign'' syndrome, as seizure recurrence almost invariably occurs after therapy withdrawal.
